#RESEARCHSPOTLIGHT
New PODCAST alert!
HIPEC: a narrative review of what HIPEC can do PART-1
https://t.co/zEDX51tMqC
"The burden of improving survival in patients with peritoneal malignancies is borne by cytoreductive surgery. HIPEC in most situations has a secondary role to play. Yet HIPEC takes the centerstage when it comes to clinical trials, debates and discussion. How did this happen? Or how did we let this happen?"
@LanaBijelicMD , chief, peritoenal malignany unit, CHU Moises Broggi and academic coordinator of #ESPS in conversation with @PSugarbaker , secretary general of the PSOGI
➡ What is the current role of HIPEC in the prevention of PM?
➡ What should be the take home message from the HIPEC T4 trial?
➡ Is peritoneal recurrence free survival a suitable end point for such a trial?
It is difficult to put all of Paul Sugarbaker's views on HIPEC and its future role into one podcast.
⛔ Will the Spanish Mitomycin C HIPEC trial be a positive trial?
Wait for part 2....
@alarjosan@AndreasBrandl8@DrSGlezMoreno@KurtSpeeten@ESSOnews@ejsotweets@indepso@IspsmHipec@NoInvisibles@NewsJellybelly@EYSAC1@DrFloresAyala@somusp9@Some4SurgeryIT1@IJGConline@agz_eriksson@Bhandoria@IJGCfellows@gyncsm
A special issue of the Journal of Gastrointestinal Oncology on PM, 'Intraperitoneal Chemotherapy for Peritoneal Metastases: HIPEC, EPIC, NIPEC, PIPAC and More' to be formally released at #PSOGI2021 (now virtual)
Editors #PaulSugarbaker#KurtVanDerSpeeten
https://t.co/uXwkrZ4GCr
Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis https://t.co/lxLpgH1rtZ
Congratulations!! This article gives hope to previously hopeless patients and encourages doctors to go for further exploration of treatment alternatives for peritoneal mets!
Extremely proud of my friends from La Paz Hospital in Madrid. Congratulations on your first lap peritonectomy and laparoscopic #hipec@MIsabelPrieto2@JavierSalinasMD Really honored to have been there mentoring you. Great teamwork!!!! @operarelcancer@aecirujanos @SPeeitoneum
PRODIGE 7 still awaited (informed initially sent to NEJM & then Lancet Onc) but this insightful commentary gives balanced discussion of data from presentations. Policy decisions on future use #HIPEC need to factor these issues in @SPeritoneum#colorectalsurgery#colorectalcancer
Excellent scientific level at @ISSPP1 & extraordinary brainstorming session for new clinical trials. Really looking forward to optimizing new ways of global collaboration and research taking advantage of the immediacy and impact of @SPeritoneum to keep all of us connected
Upcoming in @BJSurgery. Papers focussing on #NICE processes & interventional procedure approvals by @ScHARRSheffield. Positive approvals decreasing & level of evidence more demanding. https://t.co/JH1hYN5gmi